566332

Sirt1 Inhibitor VII, Inauhzin

The Sirt1 Inhibitor VII, Inauhzin controls the biological activity of Sirt1. This small molecule/inhibitor is primarily used for Cell Structure applications.

• Synonym(e): Sirt1 Inhibitor VII, Inauhzin, 10-[2-(5H-[1,2,4]triazino[5,6-b]indol-3-ylthio)butanoyl]-10H-phenothiazine, INZ
• Empirische Formel (Hill-System): C₂₅H₁₉N₅OS₂
• Molekulargewicht: 469.58
• UNSPSC-Code: 12352200
• NACRES: NA.28

Eigenschaften

• Qualitätsniveau: 100
• Assay: ≥98% (HPLC)
• Form: powder
• Wirksamkeit: 0.7 μM IC₅₀
• Hersteller/Markenname: Calbiochem^®
• Lagerbedingungen: OK to freeze; protect from light
• Farbe: beige
• Löslichkeit: DMSO: 100 mg/mL
• Versandbedingung: wet ice
• Lagertemp.: 2-8°C

Beschreibung

Allgemeine Beschreibung

A cell-permeable phenothiazine derivative that selectively inhibits SirT1 (IC₅₀ ≤2.0 µM), but not SirT2, SirT3, or HCAC8 (IC₅₀ >50 µM), activity and effectively elevates cellular p53 lysine acetylation (Effective conc. 2 µM), thereby protecting p53 lysine residues from MDM2-mediated ubiquitination without directly inhibiting MDM2 function per se or its activity toward deacetylated p53. Shown to inhibit cancer cell growth in a p53-dependent manner (IC₅₀ = 2.0 and 15.7µM, respectively, against HCT116p53^+/+ and HCT116p53^-/- cells) and synergize with Nutlin-3 (Cat. Nos. 444143, 444151, & 444152) in blocking HCT116p53^+/+ proliferation in vitro (by 29%, 76%, and >98, respectively, with 1 µM INZ alone, 4 µM Nutlin-3 alone, or in combination) and inducing HCT116p53^+/+ apoptosis in mice in vivo (3.5% above control TUNEL staining with either drug treatment alone or 25% with combined treatment; 15 mg INZ/kg via daily i.p; 150 mg Nut-3/kg b.i.d. p.o.).

A cell-permeable phenothiazine derivative that selectively inhibits SirT1 (IC₅₀ ≤2.0 µM), but not SirT2, SirT3, or HCAC8 (IC₅₀ >50 µM), activity. Effectively elevates cellular p53 lysine acetylation (Effective conc. 2 µM), thereby protecting p53 lysine residues from MDM2-mediated ubiquitination without inhibiting MDM2 activity toward deacetylated p53. Shown to inhibit cancer cell growth in a p53-dependent manner (IC₅₀ = 2.0 and 15.7µM, respectively, against HCT116p53^+/+ and HCT116p53^-/- cells) and synergize with Nutlin-3 (Cat. Nos. 444143, 444151, & 444152) in blocking HCT116p53^+/+ proliferation in vitro (1 µM INZ & 4 µM Nutlin-3) and inducing HCT116p53^+/+ apoptosis in mice in vivo (15 mg INZ/kg/d i.p; 150 mg Nut-3/kg/12 h p.o.).

Biochem./physiol. Wirkung

Cell permeable: yes

Reversible: yes

Verpackung

Packaged under inert gas

Warnhinweis

Toxicity: Standard Handling (A)

Sonstige Hinweise

Zhang, Q., et al. 2012. EMBO Mol. Med.4, 298.
Zhang, Y., et al. 2012. Cancer Biol. Ther.13, 915

Rechtliche Hinweise

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Sicherheitshinweise

• Lagerklassenschlüssel: 11 - Combustible Solids
• WGK: WGK 3
• Flammpunkt (°F): Not applicable
• Flammpunkt (°C): Not applicable